Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
SB

OTC · SBHMY

Sino Biopharmaceutical Limited

Healthcare · Biotechnology

$12.04

Down-$0.31 (-2.51%)

Updated Nov 5, 2026, 2:47 AM

SID Score

5.7/10

Composite research score

Smart Money

46/100

Neutral

Market cap
16.29B
P/E ratio
28.63
Dividend yield
1.91%
52-week range
— – —
Volume
128
Avg. volume
30

Price performance · SBHMY

SBHMY price history

1M range · 0 trading sessions · Daily adjusted prices

SBHMY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SBHMY news

The latest Smart Investors Daily articles mentioning SBHMY.

Stock researchCompany · Overview

SBHMY research

Overview

Company profile and research snapshot.

Company profile

SINO BIOPHARM UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.71
Implied upside
—
Analysts
31
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Sino Biopharmaceutical (SEHK:1177) Could Be 71% Below Fair Value Following Phase III Enrollment Update

Sino Biopharmaceutical (SEHK:1177) drew fresh attention after reporting that its subsidiary CTTQ has fully enrolled a Phase III registrational trial for TQC2731, a TSLP monoclonal antibody targeting chronic rhinosinusitis with nasal polyps. The latest TQC2731 trial update arrived after a choppy run for Sino Biopharmaceutical. The HK$4.855 share price was up 2.0% on the day yet remained down 23.66% on a year-to-date basis, with a 29.34% decline in 1-year total shareholder return. This...

Yahoo · Oct 20, 2026

Sino Biopharmaceutical (SEHK:1177) Stock Looks Expensive On Its Current Earnings

Sino Biopharmaceutical has delivered a very strong 3 year share price gain, yet the current slide over shorter periods raises a simple question for you as an investor. Is the price you see today still aligned with what the company is earning? The stock is up 115.2% over 3 years, which puts a lot of weight on the idea that its earnings can justify that kind of compounding move. The business relies on turning its drug portfolio and pipeline into steady profits, so the durability of those...

Yahoo · Oct 19, 2026

Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer

Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved the appointment of Ms. Jennie Ma as Chief Financial Officer (CFO) of the Company. In this role, Ms. Ma will oversee the Company's financial management, capital markets activities, investor relations, and strengthening its corporate compliance framework.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By